Objective: To evaluate the efficacy of Alfuzosin with or without Tolterodine, in men with Benign Prostatic Hyperplasia (BPH) having irritative (overactive bladder) symptoms.
Methodology: This randomized clinical trial was conducted at the Department of Urology, Liaquat National Hospital, Karachi, from May 3, 2012 to September 20, 2013. Seventy patients of BPH with irritative (overactive bladder) symptoms were included in the study and were divided into two groups with 35 patients in each group; one group receiving Alfuzosin with Tolterodine and other Alfuzosin only. Both the groups were compared for efficacy with decrease in International Prostatic symptom scoring of > 3 points from the baseline at 12 wks.
Results: Patients receiving Alfuzosin with Tolterodine, 27 (77.1%) reported symptomatic improvement whereas only 28.6% of patients improved with Alfuzosin only (p=0.0005).
Conclusion: This study showed that Alfuzosin in combination with Tolterodine was superior to Alfuzosin alone in patients with BPH having irritative (overactive bladder) symptoms.
Key words: Benign prostatic hyper- plasia, overactive bladder, lower urinary tract symptoms, bladder outflow obstruction, alpha-blocker, alfuzosin, antimuscarinic agent, tolterodine.
|
